Bafna Pharmaceuticals Limited is an India-based company, which is engaged in manufacturing of pharmaceutical formulations. The Company exports its products to the Europe, the United Kingdom, Australia, Sri Lanka, Africa, and Commonwealth countries.

Employees

339

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-09-09	₹301.60	-2.00%	4,475
26-09-08	₹307.75	+1.99%	6,169
26-09-07	₹301.75	+1.99%	3,079
26-09-04	₹295.85	-1.99%	4,794
26-09-03	₹301.85	-2.00%	4,454

End-of-day quote NSE India S.E.

More quotes

End-of-day quote NSE India S.E. 2026-09-09			5-day change	1st Jan Change
301.60 ^INR	-2.00%		-3.52%	+100.11%

08-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
06-22	Bafna Pharmaceuticals Limited Announces Board and Committee Changes	CI

Market Cap	7.13B 75M 64.46M 60.72M 55.34M 104M 104M 719M 278M 3.64B 282M 275M 11.51B	P/E 2025	42.6x	P/E 2026	23.3x
Enterprise Value	7.49B 78.72M 67.65M 63.73M 58.09M 109M 109M 755M 292M 3.82B 295M 289M 12.08B	EV / Sales 2025	1.38x	EV / Sales 2026	1.95x
Free-Float	10.3%	Yield 2025 *	-	Yield 2026	-

Markets		Quality
NSE India S.E.	BAFNAPH	End-of-day quote
Bombay S.E.	BAFNAPH	Delayed

08-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
06-22	Bafna Pharmaceuticals Limited Announces Board and Committee Changes	CI
05-29	Bafna Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
02-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
25-09-19	Bafna Pharmaceuticals Limited Appoints Navin Kumar as Non-Executive, Independent Director	CI
25-08-12	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
25-08-12	Bafna Pharmaceuticals Limited Approves Reconstitution of Nomination & Remuneration Committee, Effective August 12, 2025	CI
25-06-24	Bafna Pharmaceuticals Limited Announces Board and Committee Changes, Effective from June 24, 2025	CI
25-05-26	Bafna Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2025	CI
25-04-01	Bafna Pharmaceuticals Limited Announces Resignation of Krishna Yeachuri as Independent Director and Cessation as Chairman of Nomination & Remuneration Committee, Effective March 31, 2025	CI
25-02-06	Bafna Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	CI
24-11-11	Bafna Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	CI
24-08-13	Bafna Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2024	CI

Bafna Pharmaceuticals Limited Stock

Stocks

BAFNAPH

INE878I01022

Pharmaceuticals

Valuation : Bafna Pharmaceuticals Limited

Chart: Bafna Pharmaceuticals Limited

Latest news : Bafna Pharmaceuticals Limited

Quotes and Performance

Price Extremes

Managers and Directors : Bafna Pharmaceuticals Limited

Generic Pharmaceuticals

Financials

Company Profile

Quotes

1 day	-2.00%
1 week	-3.52%
Current month	-0.87%
1 month	+5.82%
3 months	+55.49%
6 months	+168.83%
Current year	+100.11%

1 week	295.85	307.75
1 month	232.95	318.5
Current year	94.77	318.5
1 year	94.77	318.5
3 years	69	318.5
5 years	69	318.5
10 years	4.4	318.5

Manager	Title	Age	Since
Bansilal Mahaveer C. Bafna CEO	Chief Executive Officer	64	1980-12-31
Melagiri Sridhar DFI	Director of Finance/CFO	-	-
A. Mohanachandran CMP	Compliance Officer	-	2024-05-28

Director	Title	Age	Since
Palamadai Krishnan Sundaresan BRD	Director/Board Member	-	-
Hemalatha Shanmugam BRD	Director/Board Member	51	2020-09-09
Akilapriya C. Raju BRD	Director/Board Member	-	2020-09-09

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BAFNA PHARMACEUTICALS LIMITED	-2.00%	-3.52%	+204.52%	+209.65%	76.79M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-1.11%	-3.32%	+17.96%	+64.97%	47.73B
OTSUKA HOLDINGS CO., LTD.	-1.06%	-5.77%	+37.73%	+115.68%	40.21B
ZYDUS LIFESCIENCES LIMITED	-1.58%	-3.46%	+11.66%	+79.48%	12.05B
CIPLA LIMITED	-1.51%	-4.21%	-11.56%	+9.52%	11.79B
KRKA, D. D.	+0.38%	-1.32%	+21.40%	+137.27%	9.16B
GEDEON RICHTER	0.00%	-4.04%	+21.19%	+33.90%	7.34B
ONO PHARMACEUTICAL CO., LTD.	-2.95%	-5.33%	+32.45%	-15.96%	7.39B
GLENMARK PHARMACEUTICALS LIMITED	-1.60%	-1.43%	+18.67%	+213.45%	7.37B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+1.32%	-1.19%	-46.13%	+22.77%	5.13B
Average	-1.01%	-1.76%	+30.79%	+87.07%	14.82B
Weighted average by Cap.	-1.05%	-2.67%	+19.47%	+80.38%

	2025	2026
Net sales	1.46B 15.33M 13.18M 12.41M 11.31M 21.17M 21.24M 147M 56.8M 743M 57.55M 56.31M 2.35B	1.51B 15.83M 13.61M 12.82M 11.68M 21.86M 21.94M 152M 58.66M 768M 59.43M 58.15M 2.43B
Net income	41.52M 437K 375K 353K 322K 603K 605K 4.18M 1.62M 21.16M 1.64M 1.6M 67.01M	111M 1.17M 1M 945K 861K 1.61M 1.62M 11.18M 4.32M 56.56M 4.38M 4.29M 179M
Net Debt	248M 2.6M 2.24M 2.11M 1.92M 3.59M 3.61M 24.95M 9.64M 126M 9.77M 9.56M 400M	354M 3.72M 3.2M 3.01M 2.75M 5.14M 5.16M 35.68M 13.79M 180M 13.97M 13.67M 571M